Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis
Psychopharmacology Bulletin · 2026
DOI: 10.64719/pb.16596 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Nicolas A Nunez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nunez, MD, MS, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Psychiatry, University of …. Hauptthemen laut MEDLINE: Naltrexone, Alcoholism, Narcotic Antagonists. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Purpose
We aimed to synthesize and provide an updated meta-analysis of the current data on extended-release naltrexone (XR-NTX) and oral naltrexone (NTX) for alcohol use disorder (AUD).
Methods
A comprehensive database search was conducted and updated on October 1, 2025. This meta-analysis encompassed randomized controlled trials (RCTs) and observational studies that compared XR-NTX and oral NTX in adults with AUD. Included studies reported outcomes on treatment persistence and healthcare utilization, specifically ED visits and inpatient hospitalizations during follow-up. Odds ratios (ORs) were computed using the Mantel-Haenszel random-effects model.
Results
Out of 101 studies screened, seven studies (N = 42,268; n = 2,103 for XR-NTX, n = 40,165 for NTX) met the inclusion criteria for the meta-analysis. Overall, treatment persistence was significantly higher with XR-NTX compared with oral NTX (OR = 1.94 [95% CI, 1.22–3.10]), with benefits observed at both three months (pooled OR = 2.24 [95% CI, 1.14–4.41], p = 0.019) and six months (OR = 1.59 [95% CI, 1.04–2.43], p = 0.032). No significant differences were observed in healthcare utilization, including all-cause ED visits (OR = 1.33 [95% CI, 0.93–1.90]) or all-cause inpatient admissions (OR = 0.84 [95% CI, 0.49–1.43]).
Conclusion
This meta-analysis suggests higher treatment persistence among patients with AUD receiving XR-NTX versus oral NTX, underscoring formulation as a key factor in persistence and retention. However, alcohol-related healthcare utilization metrics, including ED visits and hospitalizations, showed no significant between-group differences. Further pragmatic trials accounting for patient preferences, sex-specific outcomes, and barriers to care accessibility are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nunez, MD, MS, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Psychiatry, University of Utah, Salt Lake City, UT, USA.
- Ali, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA; Cleveland Clinic, Cleveland, OH, USA.
- Hassett, Mayo Medical Libraries, Mayo Clinic College of Medicine, Rochester, MN, USA.
- Singh, Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Förderung
- NCATS NIH HHS
Zitieren
APA
Nunez, N. A., Ali, H. M., Hassett, L., & Singh, B. (2026). Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.16596
Vancouver
Nunez NA, Ali HM, Hassett L, Singh B. Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.16596
BibTeX
@article{Nunez2026,
author = {Nunez, Nicolas A and Ali, Hossam M and Hassett, Leslie and Singh, Balwinder},
title = {Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis},
journal = {Psychopharmacology Bulletin},
year = {2026},
doi = {10.64719/pb.16596}
}
EUVIMED